- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
Fingerpaint Acquires Splice
California-based healthcare communications firm will be fully integrated into Fingerpaint.
Fingerpaint, a full-service health and wellness marketing firm with a global team of more than 580 people, has acquired Splice, a healthcare communications business based in Emeryville, California. Details of the transaction were not disclosed.
As part of the transaction, Splice Co-Founder Paul Hagopian will continue to lead the group’s day-to-day operations, reporting directly to McEllen. Hagopian has nearly 25 years of healthcare communications expertise and held a number of leadership positions prior to founding Splice.
For more information, click here.
What Every Pharma CEO Should Know About Unlocking the Potential of Scientific Data
December 11th 2024When integrated into pharmaceutical enterprises, scientific data has the potential to drive organizational growth and innovation. Mikael Hagstroem, CEO at leading laboratory informatics provider LabVantage Solutions, discusses how technology partners add significant value to pharmaceutical R&D, in addition to manufacturing quality.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
